First human antibodies to reach Alzheimer's target
Roche and MorphoSys announce major milestone in research collaboration
Roche and MorphoSys initiated the collaboration to develop human antibodies targeting a Roche Alzheimer's disease target in September 2000. MorphoSys used its proprietary HuCAL® (Human Combinatorial Antibody Library) library to generate several antibodies against the Roche target, achieving the first two milestones in December 2000 and March 2001. In achieving these two milestones MorphoSys delivered a series of HuCAL® antibodies which were shown to bind selectively to the Roche target in human Alzheimer brain tissue sections. For the most recent milestone MorphoSys generated HuCAL® antibodies demonstrating high affinity binding to the Roche target in both in vitro assays and in an Alzheimer's animal model. MorphoSys will receive development related milestone payments and royalties on any marketed products emerging from the collaboration.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous